BINOSTO is a prescription medication specifically designed for the treatment of osteoporosis in postmenopausal women and men at risk of fractures. Its active ingredient, alendronate sodium, belongs to a class of drugs known as bisphosphonates, which work by preventing the loss of bone mass. BINOSTO is unique because it comes in an effervescent tablet form that is dissolved in water to create a solution, making it an alternative for individuals who may have difficulty swallowing pills. By inhibiting the activity of cells that break down bone, BINOSTO helps to increase bone density and reduce the likelihood of fractures, particularly in the spine and hip. It is important for patients to follow their healthcare provider's instructions closely when taking BINOSTO, including taking it on an empty stomach and remaining upright for at least 30 minutes afterward to promote absorption and reduce the risk of gastrointestinal side effects.